154 related articles for article (PubMed ID: 11316852)
1. Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis.
Benigni A; Tomasoni S; Gagliardini E; Zoja C; Grunkemeyer JA; Kalluri R; Remuzzi G
J Am Soc Nephrol; 2001 May; 12(5):941-948. PubMed ID: 11316852
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II blockade limits tubular protein overreabsorption and the consequent upregulation of endothelin 1 gene in experimental membranous nephropathy.
Zoja C; Liu XH; Abbate M; Corna D; Schiffrin EL; Remuzzi G; Benigni A
Exp Nephrol; 1998; 6(2):121-31. PubMed ID: 9567218
[TBL] [Abstract][Full Text] [Related]
3. The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist.
Zoja C; Donadelli R; Corna D; Testa D; Facchinetti D; Maffi R; Luzzana E; Colosio V; Bertani T; Remuzzi G
Am J Kidney Dis; 1997 Feb; 29(2):254-64. PubMed ID: 9016898
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis.
Zoja C; Abbate M; Corna D; Capitanio M; Donadelli R; Bruzzi I; Oldroyd S; Benigni A; Remuzzi G
Am J Kidney Dis; 1998 Mar; 31(3):453-63. PubMed ID: 9506682
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-converting enzyme inhibition prevents glomerular-tubule disconnection and atrophy in passive Heymann nephritis, an effect not observed with a calcium antagonist.
Benigni A; Gagliardini E; Remuzzi A; Corna D; Remuzzi G
Am J Pathol; 2001 Nov; 159(5):1743-50. PubMed ID: 11696435
[TBL] [Abstract][Full Text] [Related]
6. Effect of combining ACE inhibitor and statin in severe experimental nephropathy.
Zoja C; Corna D; Rottoli D; Cattaneo D; Zanchi C; Tomasoni S; Abbate M; Remuzzi G
Kidney Int; 2002 May; 61(5):1635-45. PubMed ID: 11967013
[TBL] [Abstract][Full Text] [Related]
7. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach.
Zoja C; Corna D; Camozzi D; Cattaneo D; Rottoli D; Batani C; Zanchi C; Abbate M; Remuzzi G
J Am Soc Nephrol; 2002 Dec; 13(12):2898-908. PubMed ID: 12444208
[TBL] [Abstract][Full Text] [Related]
8. Diversities of podocyte molecular changes induced by different antiproteinuria drugs.
Xing Y; Ding J; Fan Q; Guan N
Exp Biol Med (Maywood); 2006 May; 231(5):585-93. PubMed ID: 16636307
[TBL] [Abstract][Full Text] [Related]
9. Addition of AT1 blocker fails to overcome resistance to ACE inhibition in adriamycin nephrosis.
Bos H; Henning RH; De Boer E; Tiebosch AT; De Jong PE; De Zeeuw D; Navis G
Kidney Int; 2002 Feb; 61(2):473-80. PubMed ID: 11849387
[TBL] [Abstract][Full Text] [Related]
10. Combining lisinopril and l-arginine slows disease progression and reduces endothelin-1 in passive Heymann nephritis.
Zoja C; Benigni A; Camozzi D; Corna D; Longaretti L; Todeschini M; Remuzzi G
Kidney Int; 2003 Sep; 64(3):857-63. PubMed ID: 12911535
[TBL] [Abstract][Full Text] [Related]
11. Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes.
Gagliardini E; Corna D; Zoja C; Sangalli F; Carrara F; Rossi M; Conti S; Rottoli D; Longaretti L; Remuzzi A; Remuzzi G; Benigni A
Am J Physiol Renal Physiol; 2009 Nov; 297(5):F1448-56. PubMed ID: 19675181
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes.
Lee EY; Shim MS; Kim MJ; Hong SY; Shin YG; Chung CH
Exp Mol Med; 2004 Feb; 36(1):65-70. PubMed ID: 15031673
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme inhibition prevents loss of glomerular hydraulic permeability in passive heymann nephritis.
Remuzzi A; Monaci N; Bonassi ME; Corna D; Zoja C; Mohammed EI; Remuzzi G
Lab Invest; 1999 Dec; 79(12):1501-10. PubMed ID: 10616201
[TBL] [Abstract][Full Text] [Related]
14. Nephrin dissociates from actin, and its expression is reduced in early experimental membranous nephropathy.
Yuan H; Takeuchi E; Taylor GA; McLaughlin M; Brown D; Salant DJ
J Am Soc Nephrol; 2002 Apr; 13(4):946-956. PubMed ID: 11912254
[TBL] [Abstract][Full Text] [Related]
15. Dual effects of lisinopril on puromycin aminonucleoside nephrosis in unilaterally nephrectomized rats.
Shinosaki T; Takagawa I; Sunagawa N; Yonetani Y; Kurihara H
Jpn J Pharmacol; 1997 Apr; 73(4):337-45. PubMed ID: 9165371
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass.
Lafayette RA; Mayer G; Park SK; Meyer TW
J Clin Invest; 1992 Sep; 90(3):766-71. PubMed ID: 1522231
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone.
Benigni A; Zoja C; Tomasoni S; Campana M; Corna D; Zanchi C; Gagliardini E; Garofano E; Rottoli D; Ito T; Remuzzi G
J Am Soc Nephrol; 2006 Jun; 17(6):1624-32. PubMed ID: 16687628
[TBL] [Abstract][Full Text] [Related]
18. Modulation of renal glomerular angiotensin II receptors by ace inhibition and AT1 receptor antagonism.
Haddad G; Amiri F; Garcia R
Regul Pept; 1997 Jan; 68(2):111-7. PubMed ID: 9110382
[TBL] [Abstract][Full Text] [Related]
19. Effects of treatment with angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor antagonist (AIIRA) on renal function and glomerular injury in subtotal nephrectomized rats.
Yamamoto M; Fukui M; Shou I; Wang LN; Sekizuka K; Suzuki S; Shirato I; Tomino Y
J Clin Lab Anal; 1997; 11(1):53-62. PubMed ID: 9021525
[TBL] [Abstract][Full Text] [Related]
20. Tissue- and subtype-specific modulation of angiotensin II receptors by chronic treatment with cyclosporin A, angiotensin-converting enzyme inhibitors and AT1 antagonists.
Regitz-Zagrosek V; Auch-Schwelk W; Hess B; Klein U; Duske E; Steffen C; Hildebrandt AG; Fleck E
J Cardiovasc Pharmacol; 1995 Jul; 26(1):66-72. PubMed ID: 7564368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
